trending Market Intelligence /marketintelligence/en/news-insights/trending/Buc9he6C3c-HEDM45SuaQA2 content esgSubNav
In This List

Ziopharm Oncology names president

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Ziopharm Oncology names president

ZIOPHARM Oncology Inc. said David Mauney has been promoted to president, effective Dec. 13.

Mauney joined the company in 2017 as executive vice president and chief business officer. Previously, Mauney served as managing director at Harvest Capital Strategies LLC.

Boston-based Ziopharm Oncology is a biotechnology company that focuses on acquiring, developing and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens.